(Q36861603)

16 August 2017

1 reference

title

Anticancer carrier-linked prodrugs in clinical trials (English)

1 reference

16 August 2017

Felix Kratz

1

1 reference

16 August 2017

Khalid Abu Ajaj

series ordinal

2

1 reference

16 August 2017

André Warnecke

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

1037-1058

1 reference

Transport of molecules across tumor vasculature

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Transport of molecules, particles, and cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Clinical Implications of N-(2-Hydroxypropyl)Methacrylamide Copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Polymer therapeutics: concepts and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Polymer conjugates: nanosized medicines for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Prodrugs of anthracyclines in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Monoclonal antibodies for the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Recent advances in tumor-targeting anticancer drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Modulation of camptothecin analogs in the treatment of cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

20-O-acylcamptothecin derivatives: evidence for lactone stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

The biology of the Ets1 proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

CT-2103: emerging utility and therapy for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1037

10.1517/13543784.16.7.1037

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference